Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Green Tea Lozenges for the Management of Dry Mouth

This study has been completed.
Information provided by (Responsible Party):
Scott DeRossi, Georgia Regents University Identifier:
First received: May 14, 2012
Last updated: March 17, 2015
Last verified: March 2015
Results First Received: January 23, 2015  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Conditions: Xerostomia
Sjogren Syndrome
Dry Mouth
Interventions: Dietary Supplement: MighTeaFlow
Dietary Supplement: Xylitol

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Potential candidates were identified from a pool of previously diagnosed subjects and new subjects referred to the Clinical Center for Oral Medicine, School of Dentistry, Georgia Regents University

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Subjects had a diagnosis of Xerostomia

Reporting Groups
Green Tea Lozenge


Green tea lozenge: 4-6 times daily

Placebo Xylitol lozenge 4 - 6 times daily

Participant Flow:   Overall Study
    Green Tea Lozenge     Placebo  
STARTED     30     30  
COMPLETED     26     25  
NOT COMPLETED     4     5  

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Consented subjects diagnosed with Xerostomia and meeting all inclusion exclusion criteria

Reporting Groups
Green Tea Lozenge


Green tea lozenge: 4-6 times daily



Green tea lozenge: 4-6 times daily

Total Total of all reporting groups

Baseline Measures
    Green Tea Lozenge     Placebo     Total  
Number of Participants  
[units: participants]
  30     30     60  
[units: participants]
<=18 years     0     0     0  
Between 18 and 65 years     17     16     33  
>=65 years     13     14     27  
[units: participants]
Female     30     29     59  
Male     0     1     1  
Region of Enrollment  
[units: participants]
United States     30     30     60  

  Outcome Measures

1.  Primary:   Change in Salivary Flow From Baseline   [ Time Frame: 8 weeks ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Dr. Scot DeRossi, Chairman of the ORal Medicine & Diagnostic Sciences Department
Organization: Georgia Regents University
phone: 706-721-2607

Publications automatically indexed to this study by Identifier (NCT Number):

Responsible Party: Scott DeRossi, Georgia Regents University Identifier: NCT01647737     History of Changes
Other Study ID Numbers: GHSU Lozenge Xerostomia Study
Study First Received: May 14, 2012
Results First Received: January 23, 2015
Last Updated: March 17, 2015
Health Authority: United States: Institutional Review Board